ArticleJournal of chemical information and modeling2026
Dopamine D2 Receptor Isoform Heteroreceptor Complexes with the Growth Hormone Secretagogue Receptor 1a Reveals Isoform-Specific Interaction Interface Dynamics.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Dimer for Dinner: The Impact of GHS-R1a Heterodimerization on Feeding Circuits.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dopamine D2 receptor (D2R), a class A G-protein-coupled receptor expressed in two isoforms at the central nervous system, has been implicated in several neuropsychiatric and neurodegenerative disorders. Although conventionally understood as a monomer, D2R can exist as homo- and heteroreceptor complexes, with each structural state conferring distinct functional properties. The heteromer formed by the D2R and the growth hormone secretagogue receptor (GHSR1a) has been primarily studied in the context of eating disorders, but more recently, in Parkinson's disease mouse models. Besides the neuropharmacological relevance of this heteromer, the molecular mechanisms underlying their interaction interface in complex formation have not been fully understood. Moreover, the specific contribution of each D2R isoform to both the formation and functional properties of the D2R/GHSR1a heteroreceptor complex remains to be elucidated. Therefore, in this study, we aimed to characterize the structural and dynamic differences between D2R short and long isoforms, both as monomers and within the D2R/GHSR1a heterocomplexes. Through computational methodologies including homology modeling, receptor-receptor docking, and coarse-grained molecular dynamic simulations, we observed distinct behaviors for D2R isoforms as monomers and in heteromeric assemblies with GHSR1a. Our findings showed differences in D2R isoform motions that may impact their activation along with isoform-specific interaction interfaces with GHSR1a. Furthermore, these differential interfaces promoted site-to-site and ligand-binding pocket differences for both D2R isoforms, suggesting isoform-specific allosteric regulation potentially mediated by GHSR1a within the D2R/GHSR1a heterocomplexes. Overall, our results highlight the isoform-dependent mechanisms within the D2R/GHSR1a heteromer that influence complex formation, ligand binding, and intracellular signaling, providing a framework for future therapeutic strategies targeting D2R/GHSR1a heteroreceptor complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.